Login
Subscribe
Take a FREE Trial
About Us
Contact us
RSS
25 May 2013
Search
The Pharma Letter
Home
7 Day Premium Trial
Pharmaceuticals
Biotechnology
Generics
Events
Companies
Drugs
Subscribe
Companies
Top Ten Companies //
Browse A - Z of companies
Merck KGaA
(Merck)
Merck
(Merck KGaA)
Pfizer
Roche
Novartis
GlaxoSmithKline
(GSK)
GSK
(GlaxoSmithKline)
Bristol-Myers Squibb
Lilly
Bayer
Browse the A - Z of Companies
#
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
G
Galapagos
Galaxy Biotech
Galderma
Galena BioPharma
Galenea Corp
Galenica
Galenika
Galephar Pharmaceutival Research
Gambro
Gansu Duyiwei
Gate Pharmaceuticals
GE Healthcare
Gedeon Richter
Gemin X Pharma
Gen-Probe
GENEART
Genentech
GeneraMedix
Generex Biotechnology
Genesis Biopharma
GENETRIX
Genfar SA
Genfit
Genix
Genmab
Genmed
GeNO
Genom Biotech
Genomma Lab
Genoptix
Genor BioPharma
Genoscience
Genta
Gentium
Genus Pharma
GenVec
Genzyme
Gerolymatos
Geron Corp
Gerot Lannach
Getz Pharma
Gilead Sciences
Giliad Sciences
GlaxoSmithKline
Glenmark Pharmaceuticals
Global Vision
GlobeImmune
Gloucester Pharmaceuticals
GlycoMimetics
Glycosan BioSystems
Glycotope
GlycoVaxyn
Goldshield
GP Pharm
Graceway Pharmaceuticals
Graffinity Pharmaceuticals
Green Cross
GREER Laboratories
Grifols
Grindeks
Grumant
Grunenthal
GSK
GTC Biotherapeutics
GTx
Guangdong BeiKang Pharma
Guangzhou BeBetter Medicine Technology
Guerbet
Guilford Pharmaceuticals
GVK Biosciences
GW Pharmaceuticals
Hot Topics
Most Read
Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
Proposal to list Roche's Neulastim and Actemra in New Zealand
Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
Proposal to list Roche's Neulastim and Actemra in New Zealand
Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth